Sponsored Links
| PSivida Corp Reports Favorable 12-Month Interim Safety And Efficacy Results From Iluvien™ Human PK Study |
 |
 |
 |
| Medical News - Cleft Palate | |||
|
pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leading drug delivery company, reported the interim 12-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien™. The study is being conducted by the Company's licensing partner Alimera Sciences. Iluvien is an intravitreal insert being developed for the treatment of diabetic macular edema (DME). Read more: Cleft Palate News From Medical News Today
|